CLN-049
Relapsed/Refractory Acute Myeloid Leukemia
Phase 1Active
Key Facts
Indication
Relapsed/Refractory Acute Myeloid Leukemia
Phase
Phase 1
Status
Active
Company
About Cullinan Therapeutics
Cullinan Therapeutics is a clinical-stage biopharma focused on translating deep immunology expertise into high-impact therapies for autoimmune diseases and cancer. The company employs a disciplined 'thriller or killer' portfolio strategy, yielding a focused pipeline of novel bispecific T cell engagers and kinase inhibitors. Recent milestones include completing a rolling NDA submission for zipalertinib in EGFR exon 20 NSCLC and reporting promising early clinical data for its bispecific candidates in hematology and autoimmune indications, positioning 2025 as a catalyst-rich year.
View full company profile